Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Where can you publish?
Find journals in COLORADO Profiles by department and year.

Contact Us
If you have any questions or feedback please contact us.

Melanie Sue Joy

TitleAssociate Professor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOP-Administration
Phone303/724-7416

     Bibliographic 
     selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Wen X, Joy MS, Aleksunes LM. In Vitro Transport Activity and Trafficking of MRP2/ABCC2 Polymorphic Variants. Pharm Res. 2017 Apr 12.
      View in: PubMed
    2. George B, Wen X, Mercke N, Gomez M, O'Bryant C, Bowles DW, Hu Y, Hogan SL, Joy MS, Aleksunes LM. Profiling of Kidney Injury Biomarkers in Patients Receiving Cisplatin: Time-dependent Changes in the Absence of Clinical Nephrotoxicity. Clin Pharmacol Ther. 2017 Apr; 101(4):510-518.
      View in: PubMed
    3. George B, You D, Joy MS, Aleksunes LM. Xenobiotic transporters and kidney injury. Adv Drug Deliv Rev. 2017 Jan 20.
      View in: PubMed
    4. Atilano-Roque A, Aleksunes LM, Joy MS. Bardoxolone methyl modulates efflux transporter and detoxifying enzyme expression in cisplatin-induced kidney cell injury. Toxicol Lett. 2016 Sep 30; 259:52-9.
      View in: PubMed
    5. Atilano-Roque A, Roda G, Fogueri U, Kiser JJ, Joy MS. Effect of Disease Pathologies on Transporter Expression and Function. J Clin Pharmacol. 2016 Jul; 56 Suppl 7:S205-21.
      View in: PubMed
    6. Awdishu L, Joy MS. Role of Pharmacogenomics in Kidney Disease and Injury. Adv Chronic Kidney Dis. 2016 Mar; 23(2):106-19.
      View in: PubMed
    7. Gist KM, Goldstein SL, Joy MS, Vinks AA. Milrinone Dosing Issues in Critically Ill Children With Kidney Injury: A Review. J Cardiovasc Pharmacol. 2016 Feb; 67(2):175-81.
      View in: PubMed
    8. Ternant D, Paintaud G, Trachtman H, Gipson DS, Joy MS. A possible influence of age on absorption and elimination of adalimumab in focal segmental glomerulosclerosis (FSGS). Eur J Clin Pharmacol. 2016 Feb; 72(2):253-5.
      View in: PubMed
    9. Thurman JM, Wong M, Renner B, Frazer-Abel A, Giclas PC, Joy MS, Jalal D, Radeva MK, Gassman J, Gipson DS, Kaskel F, Friedman A, Trachtman H. Complement Activation in Patients with Focal Segmental Glomerulosclerosis. PLoS One. 2015; 10(9):e0136558.
      View in: PubMed
    10. Wen X, Thorne G, Hu L, Joy MS, Aleksunes LM. Activation of NRF2 Signaling in HEK293 Cells by a First-in-Class Direct KEAP1-NRF2 Inhibitor. J Biochem Mol Toxicol. 2015 Jun; 29(6):261-6.
      View in: PubMed
    11. Margaillan G, Rouleau M, Fallon JK, Caron P, Villeneuve L, Turcotte V, Smith PC, Joy MS, Guillemette C. Quantitative profiling of human renal UDP-glucuronosyltransferases and glucuronidation activity: a comparison of normal and tumoral kidney tissues. Drug Metab Dispos. 2015 Apr; 43(4):611-9.
      View in: PubMed
    12. Trinkley KE, Nikels SM, Page RL, Joy MS. Automating and estimating glomerular filtration rate for dosing medications and staging chronic kidney disease. Int J Gen Med. 2014; 7:211-8.
      View in: PubMed
    13. Joy MS, Roberts BV, Wang J, Hu Y, Hogan SL, Falk RJ. A pilot study of leukocyte expression patterns for drug metabolizing enzyme and transporter transcripts in autoimmune glomerulonephritis. Int J Clin Pharmacol Ther. 2014 Apr; 52(4):303-13.
      View in: PubMed
    14. Ménard V, Lévesque E, Chen S, Eap O, Joy MS, Ekström L, Rane A, Guillemette C. Expression of UGT2B7 is driven by two mutually exclusive promoters and alternative splicing in human tissues: changes from prenatal life to adulthood and in kidney cancer. Pharmacogenet Genomics. 2013 Dec; 23(12):684-96.
      View in: PubMed
    15. Joy MS, Frye RF, Nolin TD, Roberts BV, La MK, Wang J, Brouwer KL, Dooley MA, Falk RJ. In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases. Pharmacotherapy. 2014 Feb; 34(2):114-22.
      View in: PubMed
    16. Roberts BV, Susano I, Gipson DS, Trachtman H, Joy MS. Contribution of renal and non-renal clearance on increased total clearance of adalimumab in glomerular disease. J Clin Pharmacol. 2013 Sep; 53(9):919-24.
      View in: PubMed
    17. Jang SY, Dooley MA, Joy MS. Impact of severe hypothyroidism on cyclophosphamide disposition and routes of metabolism and transport in a patient with treatment-resistant lupus nephritis. Ann Pharmacother. 2013 Jul-Aug; 47(7-8):e35.
      View in: PubMed
    18. Joy MS, La M, Wang J, Bridges AS, Hu Y, Hogan SL, Frye RF, Blaisdell J, Goldstein JA, Dooley MA, Brouwer KL, Falk RJ. Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis. Br J Clin Pharmacol. 2012 Sep; 74(3):445-55.
      View in: PubMed
    19. Fink JC, Joy MS, St Peter WL, Wahba IM. Finding a common language for patient safety in CKD. Clin J Am Soc Nephrol. 2012 Apr; 7(4):689-95.
      View in: PubMed
    20. Joy MS. Impact of glomerular kidney diseases on the clearance of drugs. J Clin Pharmacol. 2012 Jan; 52(1 Suppl):23S-34S.
      View in: PubMed
    21. Nyman HA, Dowling TC, Hudson JQ, Peter WL, Joy MS, Nolin TD. Comparative evaluation of the Cockcroft-Gault Equation and the Modification of Diet in Renal Disease (MDRD) study equation for drug dosing: an opinion of the Nephrology Practice and Research Network of the American College of Clinical Pharmacy. Pharmacotherapy. 2011 Nov; 31(11):1130-44.
      View in: PubMed
    22. Trachtman H, Vento S, Gipson D, Wickman L, Gassman J, Joy M, Savin V, Somers M, Pinsk M, Greene T. Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design. BMC Nephrol. 2011 Feb 10; 12:8.
      View in: PubMed
    23. Sam WJ, Joy MS. Population pharmacokinetics of mycophenolic acid and metabolites in patients with glomerulonephritis. Ther Drug Monit. 2010 Oct; 32(5):594-605.
      View in: PubMed
    24. Joy MS, Boyette T, Hu Y, Wang J, La M, Hogan SL, Stewart PW, Falk RJ, Dooley MA, Smith PC. Effects of uridine diphosphate glucuronosyltransferase 2B7 and 1A7 pharmacogenomics and patient clinical parameters on steady-state mycophenolic acid pharmacokinetics in glomerulonephritis. Eur J Clin Pharmacol. 2010 Nov; 66(11):1119-30.
      View in: PubMed
    25. Joy MS, Frye RF, Stubbert K, Brouwer KR, Falk RJ, Kharasch ED. Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases. J Clin Pharmacol. 2010 Jun; 50(6):714-20.
      View in: PubMed
    26. Stanton ML, Joy MS, Frye RF. Validation and application of a liquid chromatography-tandem mass spectrometric method for quantification of the drug transport probe fexofenadine in human plasma using 96-well filter plates. J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Feb 01; 878(3-4):497-501.
      View in: PubMed
    27. Joy MS, Gipson DS, Powell L, MacHardy J, Jennette JC, Vento S, Pan C, Savin V, Eddy A, Fogo AB, Kopp JB, Cattran D, Trachtman H. Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group. Am J Kidney Dis. 2010 Jan; 55(1):50-60.
      View in: PubMed
    28. Joy MS, Dornbrook-Lavender K, Blaisdell J, Hilliard T, Boyette T, Hu Y, Hogan SL, Candiani C, Falk RJ, Goldstein JA. CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases. Eur J Clin Pharmacol. 2009 Sep; 65(9):947-53.
      View in: PubMed
    29. Joy MS, Hilliard T, Hu Y, Hogan SL, Wang J, Falk RJ, Smith PC. Influence of clinical and demographic variables on mycophenolic acid pharmacokinetics in antineutrophil cytoplasmic antibody-associated vasculitis. Ann Pharmacother. 2009 Jun; 43(6):1020-7.
      View in: PubMed
    30. Hansen RA, Chin H, Blalock S, Joy MS. Predialysis chronic kidney disease: evaluation of quality of life in clinic patients receiving comprehensive anemia care. Res Social Adm Pharm. 2009 Jun; 5(2):143-53.
      View in: PubMed
    31. Joy MS, Hilliard T, Hu Y, Hogan SL, Dooley MA, Falk RJ, Smith PC. Pharmacokinetics of mycophenolic acid in patients with lupus nephritis. Pharmacotherapy. 2009 Jan; 29(1):7-16.
      View in: PubMed
    32. Joy MS, Gipson DS, Dike M, Powell L, Thompson A, Vento S, Eddy A, Fogo AB, Kopp JB, Cattran D, Trachtman H. Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group. Clin J Am Soc Nephrol. 2009 Jan; 4(1):39-47.
      View in: PubMed
    33. Lionaki S, Hogan SL, Falk RJ, Joy MS, Jennette CE, Nachman PH, Jennette JC. Vasculitis and anti-thyroid medication. Nephrol Dial Transplant. 2008 May; 23(5):1766-8; author reply 1768.
      View in: PubMed
    34. Joy MS, Dornbrook-Lavender KA, Chin H, Hogan SL, Denu-Ciocca C. Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients. Ann Pharmacother. 2008 Jan; 42(1):9-15.
      View in: PubMed
    35. Joy MS, Matzke GR. Nephrology pharmacy: historical reflections and future challenges. Ann Pharmacother. 2007 Nov; 41(11):1884-6.
      View in: PubMed
    36. Lionaki S, Hogan SL, Falk RJ, Joy MS, Chin H, Jennette CE, Jennette JC, Nachman PH. Association between thyroid disease and its treatment with ANCA small-vessel vasculitis: a case-control study. Nephrol Dial Transplant. 2007 Dec; 22(12):3508-15.
      View in: PubMed
    37. Joy MS, Karagiannis PC, Peyerl FW. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J Manag Care Pharm. 2007 Jun; 13(5):397-411.
      View in: PubMed
    38. Joy MS, Candiani C, Vaillancourt BA, Chin H, Hogan SL, Falk RJ. Reengineering clinical operations in a medical practice to optimize the management of anemia of chronic kidney disease. Pharmacotherapy. 2007 May; 27(5):734-44.
      View in: PubMed
    39. Joy MS, Hogan SL, Thompson BD, Finn WF, Nickeleit V. Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity. Nephrol Dial Transplant. 2007 Jul; 22(7):1963-8.
      View in: PubMed
    40. Joy MS, Kshirsagar A, Candiani C, Brooks T, Hudson JQ. Lanthanum carbonate. Ann Pharmacother. 2006 Feb; 40(2):234-40.
      View in: PubMed
    41. Joy MS, Hogan SL, Jennette JC, Falk RJ, Nachman PH. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant. 2005 Dec; 20(12):2725-32.
      View in: PubMed
    42. Joy MS, DeHart RM, Gilmartin C, Hachey DM, Hudson JQ, Pruchnicki M, Dumo P, Grabe DW, Saseen J, Zillich AJ. Clinical pharmacists as multidisciplinary health care providers in the management of CKD: a joint opinion by the Nephrology and Ambulatory Care Practice and Research Networks of the American College of Clinical Pharmacy. Am J Kidney Dis. 2005 Jun; 45(6):1105-18.
      View in: PubMed
    43. Joy MS, Nickeleit V, Hogan SL, Thompson BD, Finn WF. Calcineurin inhibitor-induced nephrotoxicity and renal expression of P-glycoprotein. Pharmacotherapy. 2005 Jun; 25(6):779-89.
      View in: PubMed
    44. Finn WF, Joy MS. A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis. Curr Med Res Opin. 2005 May; 21(5):657-64.
      View in: PubMed
    45. Dornbrook-Lavender KA, Joy MS, Denu-Ciocca CJ, Chin H, Hogan SL, Pieper JA. Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis. Pharmacotherapy. 2005 Mar; 25(3):335-44.
      View in: PubMed
    46. Zillich AJ, Saseen JJ, Dehart RM, Dumo P, Grabe DW, Gilmartin C, Hachey DM, Hudson JQ, Pruchnicki MC, Joy MS. Caring for patients with chronic kidney disease: a joint opinion of the ambulatory care and the nephrology practice and research networks of the American College of Clinical Pharmacy. Pharmacotherapy. 2005 Jan; 25(1):123-43.
      View in: PubMed
    47. Joy MS, Kshirsagar AV, Franceschini N. Calcimimetics and the treatment of primary and secondary hyperparathyroidism. Ann Pharmacother. 2004 Nov; 38(11):1871-80.
      View in: PubMed
    48. Finn WF, Joy MS, Hladik G. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol. 2004 Sep; 62(3):193-201.
      View in: PubMed
    49. Franceschini N, Joy MS, Kshirsagar A. Cinacalcet HCl: a calcimimetic agent for the management of primary and secondary hyperparathyroidism. Expert Opin Investig Drugs. 2003 Aug; 12(8):1413-21.
      View in: PubMed
    50. Joy MS, Finn WF. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis. 2003 Jul; 42(1):96-107.
      View in: PubMed
    51. Joy MS. Darbepoetin alfa: a novel erythropoiesis-stimulating protein. Ann Pharmacother. 2002 Jul-Aug; 36(7-8):1183-92.
      View in: PubMed
    52. Joy MS, Cefalu WT, Hogan SL, Nachman PH. Long-term glycemic control measurements in diabetic patients receiving hemodialysis. Am J Kidney Dis. 2002 Feb; 39(2):297-307.
      View in: PubMed
    53. ten Holder SM, Joy MS, Falk RJ. Cutaneous and systemic manifestations of drug-induced vasculitis. Ann Pharmacother. 2002 Jan; 36(1):130-47.
      View in: PubMed
    54. Matzke GR, Frye RF, Joy MS, Palevsky PM. Determinants of ceftriaxone clearance by continuous venovenous hemofiltration and hemodialysis. Pharmacotherapy. 2000 Jun; 20(6):635-43.
      View in: PubMed
    55. Matzke GR, Frye RF, Joy MS, Palevsky PM. Determinants of ceftazidime clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Antimicrob Agents Chemother. 2000 Jun; 44(6):1639-44.
      View in: PubMed
    56. Kshirsagar AV, Joy MS, Hogan SL, Falk RJ, Colindres RE. Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials. Am J Kidney Dis. 2000 Apr; 35(4):695-707.
      View in: PubMed
    57. Joy MS, Neyhart CD, Dooley MA. A multidisciplinary renal clinic for corticosteroid-induced bone disease. Pharmacotherapy. 2000 Feb; 20(2):206-16.
      View in: PubMed
    58. Joy MS, Matzke GR, Frye RF, Palevsky PM. Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Am J Kidney Dis. 1998 Jun; 31(6):1019-27.
      View in: PubMed
    59. Nachman PH, Joy MS. Glycosylated hemoglobin in the care of patients with diabetes mellitus. ANNA J. 1998 Apr; 25(2):245-6.
      View in: PubMed
    60. Joy MS, Matzke GR, Armstrong DK, Marx MA, Zarowitz BJ. A primer on continuous renal replacement therapy for critically ill patients. Ann Pharmacother. 1998 Mar; 32(3):362-75.
      View in: PubMed
    61. Joy MS. Clonazepam: benzodiazepine therapy for the restless legs syndrome. ANNA J. 1997 Dec; 24(6):686-9.
      View in: PubMed
    62. Wanless RS, Anderson K, Joy M, Joseph SP. Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias. Am Heart J. 1997 Apr; 133(4):441-6.
      View in: PubMed
    63. Cleary DJ, Matzke GR, Alexander AC, Joy MS. Medication knowledge and compliance among patients receiving long-term dialysis. Am J Health Syst Pharm. 1995 Sep 01; 52(17):1895-900.
      View in: PubMed
    64. Joy M, Hubner PJ, Thomas RD, Cummin P, Dews I, Williams H, Shahrabani R. Long term use of enalapril in the treatment of patients with congestive heart failure. Int J Cardiol. 1987 Aug; 16(2):137-44.
      View in: PubMed
    65. Given-Wilson R, Joy M. Once daily timolol in the prophylaxis of angina pectoris. Int J Cardiol. 1985 Oct; 9(2):191-8.
      View in: PubMed
    Joy's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts
    _
    Co-Authors
    _
    Similar People
    _
    Same Department
    Physical Neighbors
    _

    Copyright © 2012 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.5.1)